Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ: GLUE · Real-Time Price · USD
4.150
-0.080 (-1.89%)
May 30, 2025, 2:47 PM - Market open
Monte Rosa Therapeutics Analyst Ratings
Total Analysts
3
Consensus Rating
Buy
Price Target
$14.33
Upside
+245.30%
Ratings History
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Hold Maintains $11 → $10 | Hold | Maintains | $11 → $10 | +140.96% | Mar 21, 2025 |
| Wedbush | Wedbush | Buy Maintains $15 → $17 | Buy | Maintains | $15 → $17 | +309.64% | Mar 21, 2025 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 → $11 | Buy → Hold | Downgrades | $14 → $11 | +165.06% | Dec 19, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +165.06% | Sep 12, 2024 |
| Wells Fargo | Wells Fargo | Buy Maintains $18 → $17 | Buy | Maintains | $18 → $17 | +309.64% | Aug 12, 2024 |
| Piper Sandler | Piper Sandler | Buy Reiterates $16 | Buy | Reiterates | $16 | +285.54% | Jun 28, 2024 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +165.06% | May 22, 2024 |
| Wedbush | Wedbush | Buy Initiates $11 | Buy | Initiates | $11 | +165.06% | Feb 15, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $11 | Buy | Maintains | $31 → $11 | +165.06% | Oct 19, 2023 |
| Credit Suisse | Credit Suisse | Hold Reiterates $11 | Hold | Reiterates | $11 | +165.06% | Aug 11, 2023 |
| Credit Suisse | Credit Suisse | Hold Reiterates $11 | Hold | Reiterates | $11 | +165.06% | May 12, 2023 |
| Credit Suisse | Credit Suisse | Hold Maintains $12 → $11 | Hold | Maintains | $12 → $11 | +165.06% | Mar 17, 2023 |
| Wells Fargo | Wells Fargo | Hold → Buy Upgrades $19 | Hold → Buy | Upgrades | $19 | +357.83% | Jan 3, 2023 |
| UBS | UBS | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +430.12% | Oct 13, 2022 |
| Jefferies | Jefferies | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +381.93% | Aug 15, 2022 |
| Piper Sandler | Piper Sandler | Buy Maintains $40 → $21 | Buy | Maintains | $40 → $21 | +406.02% | May 12, 2022 |
Upgrade to Pro
Get stock forecasts from Wall Street's highest rated professionals
Get much more with Stock Analysis Pro
- Investment ideas from the top Wall Street analysts
- Unlimited access to all data and tools
- Advanced analyst filtering and sorting options
- Up to 10 years of analyst rating history
Analyst Star Rankings
Our analyst star rankings are based on these four factors
- Success Rate
- The percentage of ratings that are profitable.
- Average Return
- The average percentage return within one year of the rating.
- Rating Count
- The more ratings the analyst has provided, the higher the score.
- Recency
- Ratings provided within the past year contribute to a higher score.